PHIL Stock Overview
A biotechnology company, develops drugs for oncology and chronic inflammatory diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Philogen S.p.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €20.00 |
| 52 Week High | €21.90 |
| 52 Week Low | €16.05 |
| Beta | 0.19 |
| 11 Month Change | -8.26% |
| 3 Month Change | 0% |
| 1 Year Change | 22.32% |
| 33 Year Change | 49.93% |
| 5 Year Change | n/a |
| Change since IPO | 19.83% |
Recent News & Updates
Analyst Forecasts For Philogen S.p.A. (BIT:PHIL) Are Surging Higher
Apr 14
Earnings Update: Philogen S.p.A. (BIT:PHIL) Just Reported And Analysts Are Boosting Their Estimates
Mar 31Recent updates
Analyst Forecasts For Philogen S.p.A. (BIT:PHIL) Are Surging Higher
Apr 14Earnings Update: Philogen S.p.A. (BIT:PHIL) Just Reported And Analysts Are Boosting Their Estimates
Mar 31What Philogen S.p.A.'s (BIT:PHIL) P/S Is Not Telling You
Feb 24Here's Why We're Watching Philogen's (BIT:PHIL) Cash Burn Situation
Jun 03Shareholder Returns
| PHIL | IT Biotechs | IT Market | |
|---|---|---|---|
| 7D | -1.0% | -4.6% | 0.2% |
| 1Y | 22.3% | -2.1% | 16.9% |
Return vs Industry: PHIL exceeded the Italian Biotechs industry which returned -1% over the past year.
Return vs Market: PHIL exceeded the Italian Market which returned 15.1% over the past year.
Price Volatility
| PHIL volatility | |
|---|---|
| PHIL Average Weekly Movement | 2.6% |
| Biotechs Industry Average Movement | 7.2% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in IT Market | 6.5% |
| 10% least volatile stocks in IT Market | 2.5% |
Stable Share Price: PHIL has not had significant price volatility in the past 3 months.
Volatility Over Time: PHIL's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 165 | Dario Neri | www.philogen.com |
Philogen S.p.A., a biotechnology company, develops drugs for oncology and chronic inflammatory diseases. It is developing Nidlegy, a combination of the immunocytokines L19IL2 and L19TNF developed intralesional treatment for locoregional melanoma and non-melanoma skin cancers; Fibromun, a human immunomodulatory product consisting of L19 antibody and TNF to treat soft tissue sarcoma, leiomyosarcoma, and glioma; and Darleukin (L19IL2), a human immunostimulatory product consisting of the human L19 antibody fused to the human cytokine interleukin-2 (IL2), which is in phase II clinical trial for the treatment of non-small cell lung cancer. The company is also developing Dodekin, a human immunostimulatory product that comprises vascular targeting antibody fused to interleukin-12 that is in phase I/II clinical trial to treat advanced solid tumors; Dekavil (F8IL10), an anti-inflammatory product, which is in phase II clinical trial for the treatment of chronic inflammatory disorders; Onco IX (PHC-102), a 99mTc labelled small molecule radiotracer for the non-invasive detection of carbonic anhydrase IX (CAIX) expressed on the surface of solid tumors that is in phase 1 clinical trial; and OncoFAP, a small molecule radiotracer for the non-invasive detection of various metastatic solid tumors targeting fibroblast activation protein, which is in phase 1 clinical trial.
Philogen S.p.A. Fundamentals Summary
| PHIL fundamental statistics | |
|---|---|
| Market cap | €805.79m |
| Earnings (TTM) | -€6.16m |
| Revenue (TTM) | €24.73m |
32.6x
P/S Ratio-130.8x
P/E RatioIs PHIL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PHIL income statement (TTM) | |
|---|---|
| Revenue | €24.73m |
| Cost of Revenue | €17.46m |
| Gross Profit | €7.27m |
| Other Expenses | €13.43m |
| Earnings | -€6.16m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Sep 25, 2024
| Earnings per share (EPS) | -0.15 |
| Gross Margin | 29.39% |
| Net Profit Margin | -24.91% |
| Debt/Equity Ratio | 3.1% |
How did PHIL perform over the long term?
See historical performance and comparison